keyword
MENU ▼
Read by QxMD icon Read
search

stage IV melanoma

keyword
https://www.readbyqxmd.com/read/27887672/cost-of-cutaneous-melanoma-by-tumor-stage-a-descriptive-analysis
#1
P Serra-Arbeloa, Á O Rabines-Juárez, M S Álvarez-Ruiz, F Guillén-Grima
BACKGROUND AND OBJECTIVE: The basis for optimal resource allocation is an understanding of requirements during the diagnostic and treatment phases. Costs associated with the rising incidence of cutaneous melanoma are considerable. We undertook an up-to-date analysis of the cost of diagnosis, treatment, and follow-up according to tumor stage. METHODS: We constructed descriptive tables following a theoretical model of direct costs based on amounts published in directives for the Spanish national health system and in international guidelines for managing cutaneous melanoma according to stage at diagnosis and clinical course...
November 22, 2016: Actas Dermo-sifiliográficas
https://www.readbyqxmd.com/read/27878858/non-invasive-tools-for-the-diagnosis-of-cutaneous-melanoma
#2
REVIEW
C Fink, H A Haenssle
BACKGROUND: While the excisional biopsy and histological examination of suspicious lesions remains the current gold standard for diagnosing cutaneous melanoma (CM), there is a demand for more objective and non-invasive examination methods that may support clinicians in their decision when to biopsy or not. METHODS: This review is based on publications and guidelines retrieved by a selective search in PubMed and MEDLINE and focused on non-invasive diagnostic strategies for detecting melanoma...
November 22, 2016: Skin Research and Technology
https://www.readbyqxmd.com/read/27878363/improvement-of-overall-survival-in-stage-iv-melanoma-patients-during-2011-2014-analysis-of-real-world-data-in-441-patients-of-the-german-central-malignant-melanoma-registry-cmmr
#3
Andrea Forschner, Felizitas Eichner, Teresa Amaral, Ulrike Keim, Claus Garbe, Thomas Kurt Eigentler
BACKGROUND: During 2011 and 2014, new treatment modalities like tyrosine kinase inhibitors and checkpoint inhibitors were introduced into the therapy of metastatic melanoma. This study addresses the question whether overall survival (OS) of metastatic melanoma patients has already been improved in 441 patients diagnosed with metastatic melanoma between 2011 and 2014 in the real-world setting at the University Hospital Tuebingen. METHODS: All patients were documented with their different therapies by the CMMR and followed up until March 2016...
November 22, 2016: Journal of Cancer Research and Clinical Oncology
https://www.readbyqxmd.com/read/27867747/early-diagnosis-of-genital-mucosal-melanoma-how-good-are-our-dermoscopic-criteria
#4
Tova Rogers, Melissa Pulitzer, Maria L Marino, Ashfaq A Marghoob, Oliver Zivanovic, Michael A Marchetti
BACKGROUND: There are limited studies on the dermoscopic features of mucosal melanoma, particularly early-stage lesions. Described criteria include the presence of blue, gray, or white colors, with a reported sensitivity of 100%. It is unclear if these features will aid in the detection of early mucosal melanoma or improve diagnostic accuracy compared to naked-eye examination alone. CASE: An Asian female in her fifties was referred for evaluation of an asymptomatic, irregularly pigmented patch of the clitoral hood and labia minora of unknown duration...
October 2016: Dermatology Practical & Conceptual
https://www.readbyqxmd.com/read/27853637/vaccination-of-stage-iii-iv-melanoma-patients-with-long-ny-eso-1-peptide-and-cpg-b-elicits-robust-cd8-and-cd4-t-cell-responses-with-multiple-specificities-including-a-novel-dr7-restricted-epitope
#5
P Baumgaertner, C Costa Nunes, A Cachot, H Maby-El Hajjami, L Cagnon, M Braun, L Derré, J-P Rivals, D Rimoldi, S Gnjatic, S Abed Maillard, P Marcos Mondéjar, M P Protti, E Romano, O Michielin, P Romero, D E Speiser, C Jandus
Long synthetic peptides and CpG-containing oligodeoxynucleotides are promising components for cancer vaccines. In this phase I trial, 19 patients received a mean of 8 (range 1-12) monthly vaccines s.c. composed of the long synthetic NY-ESO-179-108 peptide and CpG-B (PF-3512676), emulsified in Montanide ISA-51. In 18/18 evaluable patients, vaccination induced antigen-specific CD8(+) and CD4(+) T-cell and antibody responses, starting early after initiation of immunotherapy and lasting at least one year. The T-cells responded antigen-specifically, with strong secretion of IFNγ and TNFα, irrespective of patients' HLAs...
2016: Oncoimmunology
https://www.readbyqxmd.com/read/27845904/the-evaluation-of-immunotherapy-and-chemotherapy-treatment-on-melanoma-a-network-meta-analysis
#6
BaSang CiRen, Xinhua Wang, Ziwen Long
BACKGROUND: Melanoma is a highly malignant tumor that develops from a neural crest derivative called melanocytes. Chemotherapy is recommended for patients with stage III/IV melanoma. Immunomodulation has also been shown to effectively improve the survival rate of such patients. In the current study, we aimed to perform a network meta-analysis on the therapeutic value of chemotherapy and immunotherapy on melanoma. RESULTS: Twenty randomized controlled trials (RCTs) were enrolled in the study...
November 10, 2016: Oncotarget
https://www.readbyqxmd.com/read/27843913/quercetin-as-an-emerging-anti-melanoma-agent-a-four-focus-area-therapeutic-development-strategy
#7
REVIEW
Zoey Harris, Micah G Donovan, Gisele Morais Branco, Kirsten H Limesand, Randy Burd
Replacing current refractory treatments for melanoma with new prevention and therapeutic approaches is crucial in order to successfully treat this aggressive cancer form. Melanoma develops from neural crest cells, which express tyrosinase - a key enzyme in the pigmentation pathway. The tyrosinase enzyme is highly active in melanoma cells and metabolizes polyphenolic compounds; tyrosinase expression thus makes feasible a target for polyphenol-based therapies. For example, quercetin (3,3',4',5,7-pentahydroxyflavone) is a highly ubiquitous and well-classified dietary polyphenol found in various fruits, vegetables, and other plant products including onions, broccoli, kale, oranges, blueberries, apples, and tea...
2016: Frontiers in Nutrition
https://www.readbyqxmd.com/read/27843625/safety-and-immunogenicity-of-the-prame-cancer-immunotherapeutic-in-metastatic-melanoma-results-of-a-phase-i-dose-escalation-study
#8
R Gutzmer, L Rivoltini, E Levchenko, A Testori, J Utikal, P A Ascierto, L Demidov, J J Grob, R Ridolfi, D Schadendorf, P Queirolo, A Santoro, C Loquai, B Dreno, A Hauschild, E Schultz, T P Lesimple, N Vanhoutte, B Salaun, M Gillet, S Jarnjak, P M De Sousa Alves, J Louahed, V G Brichard, F F Lehmann
PURPOSE: The PRAME tumour antigen is expressed in several tumour types but in few normal adult tissues. A dose-escalation phase I/II study (NCT01149343) assessed the safety, immunogenicity and clinical activity of the PRAME immunotherapeutic (recombinant PRAME protein (recPRAME) with the AS15 immunostimulant) in patients with advanced melanoma. Here, we report the phase I dose-escalation study segment. PATIENTS AND METHODS: Patients with stage IV PRAME-positive melanoma were enrolled to 3 consecutive cohorts to receive up to 24 intramuscular injections of the PRAME immunotherapeutic...
2016: ESMO Open
https://www.readbyqxmd.com/read/27810611/management-of-skin-defect-following-resection-of-stage-iv-scalp-melanoma-a-case-report
#9
Yana Puckett, Eileen Bui, Sharmila Dissanaike
INTRODUCTION: Surgical defect left following excision of a large and neglected scalp melanoma of can pose a significant challenge for the surgeon. Scalp reconstruction encompasses options such as skin flaps, grafts, and various mechanical techniques. In scalp excision that involves dissection beyond the galea, skin grafts and flaps may not take well and not enough tissue may be available for a skin flap. PRESENTATION OF CASE: We present the case of a 64 year-old male with a giant scalp melanoma...
October 17, 2016: International Journal of Surgery Case Reports
https://www.readbyqxmd.com/read/27793694/small-molecule-inhibition-of-polo-like-kinase-1-by-volasertib-bi-6727-causes-significant-melanoma-growth-delay-and-regression-in%C3%A2-vivo
#10
Brian D Cholewa, Mary A Ndiaye, Wei Huang, Xiaoqi Liu, Nihal Ahmad
The objective of this study was to determine the therapeutic potential of polo-like kinase 1 (Plk1) inhibition in melanoma, in vivo. Employing Vectra technology, we assessed the Plk1 expression profile in benign nevi, malignant (stages I-IV) and metastatic melanomas. We found a significant elevation of Plk1 immunostaining in melanoma tissues. Further, a second generation small molecule Plk1 inhibitor, BI 6727, resulted in reductions in growth, viability and clonogenic survival, as well as an increase in apoptosis of A375 and Hs 294T melanoma cells...
October 25, 2016: Cancer Letters
https://www.readbyqxmd.com/read/27786364/usefulness-of-serum-5-s-cysteinyl-dopa-as-a-biomarker-for-predicting-prognosis-and-detecting-relapse-in-patients-with-advanced-stage-malignant-melanoma
#11
Hiroshi Umemura, Osamu Yamasaki, Tatsuya Kaji, Masaki Otsuka, Kenji Asagoe, Minoru Takata, Keiji Iwatsuki
With the recent development of novel molecular targeted drugs for advanced stage malignant melanoma (MM), including RAF and mitogen-activated protein kinase kinase inhibitors and immune checkpoint blockers, the early detection of relapse is important for managing patients with MM. In this study, we retrospectively analyzed two conventional serum biomarkers, 5-S-cysteinyl-dopa and lactate dehydrogenase, in patients with MM (n = 140) who were treated at a single Japanese institute from June 2007 to June 2015...
October 27, 2016: Journal of Dermatology
https://www.readbyqxmd.com/read/27779995/second-primary-melanoma-risk-factors-histopathologic-features-survival-and-implications-for-follow-up
#12
Maris S Jones, Hitoe Torisu-Itakura, Devin C Flaherty, Hans F Schoellhammer, Jihey Lee, Myung-Shim Sim, Mark B Faries
The impact on survival of a second primary melanoma (SPM) is unclear. We used our melanoma center's database to examine clinicopathologic risk factors and outcomes of stage 0 to IV cutaneous melanoma in patients with one versus two primaries. Among 12,325 patients with primary melanoma, 969 (7.86%) developed SPM. SPMs were significantly thinner than autologous primary melanomas (P = 0.01), and 451 SPM patients had better overall and melanoma-specific survival than 451 prognostically matched non-SPM patients (P < 0...
October 2016: American Surgeon
https://www.readbyqxmd.com/read/27775691/targeting-melanoma-with-front-line-therapy-does-not-abrogate-nodal-expressing-tumor-cells
#13
Mary Jc Hendrix, Irawati Kandela, Andrew P Mazar, Elisabeth A Seftor, Richard Eb Seftor, Naira V Margaryan, Luigi Strizzi, George F Murphy, Georgina V Long, Richard A Scolyer
Metastatic melanoma is a highly aggressive skin cancer with a poor prognosis. It is the leading cause of skin cancer deaths with a median overall survival for advanced-stage metastatic disease of <6 months. Despite advances in the field with conventional and targeted therapies, the heterogeneity of melanoma poses the greatest ongoing challenge, ultimately leading to relapse and progression to a more drug-resistant tumor in most patients. Particularly noteworthy are recent findings, indicating that these therapies exert selective pressure on tumors resulting in the activation of pathways associated with cancer stem cells that are unresponsive to current therapy...
October 24, 2016: Laboratory Investigation; a Journal of Technical Methods and Pathology
https://www.readbyqxmd.com/read/27764805/nivolumab-for-advanced-melanoma-pretreatment-prognostic-factors-and-early-outcome-markers-during-therapy
#14
Yoshio Nakamura, Shigehisa Kitano, Akira Takahashi, Arata Tsutsumida, Kenjiro Namikawa, Keiji Tanese, Takayuki Abe, Takeru Funakoshi, Noboru Yamamoto, Masayuki Amagai, Naoya Yamazaki
BACKGROUND: An anti-programmed cell death protein 1 monoclonal antibody, nivolumab, is one of the most effective drugs for advanced melanoma. Tumor cell-derived or immune cell-derived markers and clinical predictors such as serum lactate dehydrogenase (LDH) and cutaneous adverse events, have already been described as prognostic factors for advanced melanoma treated with nivolumab. We sought to identify further clinical predictors that can be determined in routine clinical practice. METHODS: We retrospectively analyzed clinical findings of 98 consecutive patients with unresectable stage III or IV melanoma treated with nivolumab, at the National Cancer Center Hospital or at Keio University Hospital, in Tokyo, Japan, between July 2014 and July 2016...
October 15, 2016: Oncotarget
https://www.readbyqxmd.com/read/27748045/a-phase-i-trial-of-panobinostat-lbh589-in-patients-with-metastatic-melanoma
#15
Nageatte Ibrahim, Elizabeth I Buchbinder, Scott R Granter, Scott J Rodig, Anita Giobbie-Hurder, Carla Becerra, Argyro Tsiaras, Evisa Gjini, David E Fisher, F Stephen Hodi
Epigenetic alterations by histone/protein deacetylases (HDACs) are one of the many mechanisms that cancer cells use to alter gene expression and promote growth. HDAC inhibitors have proven to be effective in the treatment of specific malignancies, particularly in combination with other anticancer agents. We conducted a phase I trial of panobinostat in patients with unresectable stage III or IV melanoma. Patients were treated with oral panobinostat at a dose of 30 mg daily on Mondays, Wednesdays, and Fridays (Arm A)...
November 2016: Cancer Medicine
https://www.readbyqxmd.com/read/27705749/high-gdf-15-serum-levels-independently-correlate-with-poorer-overall-survival-of-tumor-free-stage-iii-and-unresectable-stage-iv-melanoma-patients
#16
Benjamin Weide, Tina Schäfer, Alexander Martens, Anastasia Kuzkina, Laura Uder, Seema Noor, Claus Garbe, Patrick N Harter, Michel Mittelbronn, Jörg Wischhusen
Biomarkers are strongly needed for diagnostic surveillance of metastatic melanoma patients. Based on its known association with tumor metastasis and its ability to induce cancer cachexia we investigated serum levels of growth and differentiation factor 15 (sGDF-15) as marker for overall survival (OS). sGDF-15 was retrospectively measured by ELISA in 761 samples obtained at distinct time points during routine clinical care of stage III/IV melanoma patients. In the entire cohort sGDF-15 ≥1.5ng/mL was strongly associated with reduced OS after assessment...
July 22, 2016: Journal of Investigative Dermatology
https://www.readbyqxmd.com/read/27703530/contrary-melanoma-associated-antigen-a-expression-at-the-tumor-front-and-center-a-comparative-analysis-of-stage-i-and-iv-head-and-neck-squamous-cell-carcinoma
#17
Stefan Hartmann, Muna Brisam, Stephan Rauthe, Oliver Driemel, Roman C Brands, Andreas Rosenwald, Alexander C Kübler, Urs D A Müller-Richter
There is a growing body of evidence indicating that several melanoma-associated antigen-A (MAGE-A) subgroups contribute to the malignancy of head and neck cancer. The present study retrospectively analyzed the expression of all known MAGE-A subgroups in the tumor front and center of 38 head and neck cancer patients (Union for International Cancer Control stage I or IV) by immunohistochemistry. MAGE-A1, -A6, -A8, -A9 and -A11 were expressed at significantly higher levels at the tumor front of stage IV specimens compared with the tumor front of stage I specimens...
October 2016: Oncology Letters
https://www.readbyqxmd.com/read/27701080/cobimetinib-a-novel-mek-inhibitor-for-metastatic-melanoma
#18
Jessie Signorelli, Arpita Shah Gandhi
OBJECTIVE: To review and summarize data on cobimetinib, which was approved by the US Food and Drug Administration (FDA) in November 2015 for use in combination with vemurafenib for unresectable or metastatic melanoma with a BRAFV600E or V600K mutation. DATA SOURCES: A literature search using PubMed was conducted using the terms cobimetinib, MEK inhibitor, and melanoma from January 2000 to June 2016. STUDY SELECTION AND DATA EXTRACTION: The literature search was confined to human studies published in English...
October 3, 2016: Annals of Pharmacotherapy
https://www.readbyqxmd.com/read/27696578/systematic-review-of-psychosocial-outcomes-for-patients-with-advanced-melanoma
#19
Jeff Dunn, Maggie Watson, Joanne F Aitken, Melissa K Hyde
BACKGROUND: New advanced melanoma therapies are associated with improved survival however quality of survivorship, particularly psychosocial outcomes, for patients overall and those treated with newer therapies is unclear. OBJECTIVE: Synthesise qualitative and quantitative evidence about psychosocial outcomes for advanced (stage III/IV) melanoma patients. METHODS: Five databases were searched (01/01/1980 to 31/01/2016). INCLUSION CRITERIA: advanced melanoma patients or sub-group analysis; assessed psychosocial outcomes; English language...
October 3, 2016: Psycho-oncology
https://www.readbyqxmd.com/read/27686483/treatment-outcomes-in-pediatric-melanoma-are-there-benefits-to-specialized-care
#20
Benjamin Freemyer, Emma Hamilton, Carla L Warneke, Ali M Ali, Cynthia Herzog, Andrea Hayes-Jordan, Mary Austin
PURPOSE: The purpose of this study was to evaluate the impact of hospital specialization on survival in pediatric melanoma. METHODS: We reviewed all patients under 18years old with cutaneous melanoma evaluated at MD Anderson Cancer Center, a National Cancer Institute (NCI)-designated center, from 2000 to 2014. We compared overall survival (OS) and disease-free survival (DFS) between patients who underwent all treatments at MDACC (Group A, n=146) and those who underwent initial surgical treatment at a non-NCI center (Group B, n=58)...
September 17, 2016: Journal of Pediatric Surgery
keyword
keyword
10968
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"